Literature DB >> 17983659

Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system.

Jaime Belmares1, Dale N Gerding, Jorge P Parada, Scott Miskevics, Frances Weaver, Stuart Johnson.   

Abstract

OBJECTIVES: To determine the response rate of Clostridium difficile disease (CDD) to treatment with metronidazole and assess a scoring system to predict response to treatment with metronidazole when applied at the time of CDD diagnosis.
METHODS: Retrospective review of patients with CDD who received primary treatment with metronidazole. We defined success as diarrhea resolution within 6 days of therapy. A CDD score was defined prospectively using variables suggested to correlate with disease severity.
RESULTS: Among 102 evaluable patients, 72 had a successful response (70.6%). Twenty-one of the remaining 30 patients eventually responded to metronidazole, but required longer treatment, leaving 9 'true failures'. The mean CDD score was higher among true failures (2.89+/-1.4) than among all metronidazole responders (0.77+/-1.0) (p<.0001). The score was greater than 2 in 67% of true failures and 2 or less in 94% of metronidazole responders. Leukocytosis and abnormal CT scan findings were individual factors associated with a higher risk of metronidazole failure.
CONCLUSIONS: Only 71% of CDD patients responded to metronidazole within 6 days, but the overall response rate was 91%. A CDD score greater than 2 was associated with metronidazole failure in 6 of 9 true failures. The CDD score will require prospective validation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17983659     DOI: 10.1016/j.jinf.2007.09.015

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  40 in total

1.  Can metronidazole still be used for treatment of Clostridium difficile infections?

Authors:  Haihui Huang; Carl Erik Nord
Journal:  Curr Infect Dis Rep       Date:  2009-01       Impact factor: 3.725

2.  Management of severe Clostridium difficile-associated diarrhea.

Authors:  Michael J Krier; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2009-02-19       Impact factor: 3.199

3.  Antibiotic Regimen after a Total Abdominal Colectomy with Ileostomy for Fulminant Clostridium difficile Colitis: A Multi-Institutional Study.

Authors:  Gwendolyn M van der Wilden; Melanie P Subramanian; Yuchiao Chang; Lawrence Lottenberg; Robert Sawyer; Stephen W Davies; Paula Ferrada; Jinfeng Han; Alec Beekley; George C Velmahos; Marc A de Moya
Journal:  Surg Infect (Larchmt)       Date:  2015-06-12       Impact factor: 2.150

Review 4.  Clostridium difficile infection: new insights into management.

Authors:  Sahil Khanna; Darrell S Pardi
Journal:  Mayo Clin Proc       Date:  2012-11       Impact factor: 7.616

5.  Intestinal inflammatory biomarkers and outcome in pediatric Clostridium difficile infections.

Authors:  Rana E El Feghaly; Jennifer L Stauber; Phillip I Tarr; David B Haslam
Journal:  J Pediatr       Date:  2013-09-04       Impact factor: 4.406

6.  Predictors of mortality attributable to Clostridium difficile infection in patients with underlying malignancy.

Authors:  Young Kyung Yoon; Min Ja Kim; Jang Wook Sohn; Hye Suk Kim; Yoon Ji Choi; Jung Sun Kim; Seung Tae Kim; Kyong Hwa Park; Seok Jin Kim; Byung Soo Kim; Sang Won Shin; Yeul Hong Kim; Yong Park
Journal:  Support Care Cancer       Date:  2014-03-05       Impact factor: 3.603

Review 7.  Clostridium difficile infection: management strategies for a difficult disease.

Authors:  Sahil Khanna; Darrell S Pardi
Journal:  Therap Adv Gastroenterol       Date:  2014-03       Impact factor: 4.409

8.  Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection.

Authors:  T Louie; M Miller; C Donskey; K Mullane; E J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

9.  The A, B, BI, and Cs of Clostridium difficile.

Authors:  Erik R Dubberke
Journal:  Clin Infect Dis       Date:  2009-10-15       Impact factor: 9.079

10.  Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection.

Authors:  Rana E El Feghaly; Jennifer L Stauber; Elena Deych; Carlos Gonzalez; Phillip I Tarr; David B Haslam
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.